Trial Outcomes & Findings for Treatment of Negative Symptoms of Schizophrenia With Transcranial Magnetic Stimulation (TMS) (NCT NCT00517075)

NCT ID: NCT00517075

Last Updated: 2017-01-13

Results Overview

Recruitment status

TERMINATED

Study phase

PHASE2

Target enrollment

14 participants

Primary outcome timeframe

At baseline, every 2 weeks during rTMS sessions, and at monthly follow-up visits.

Results posted on

2017-01-13

Participant Flow

P.I. has left the institution and NYSPI has no access to the data. Results will not be analyzed or presented.

Participant milestones

Participant milestones
Measure
High Frequency rTMS
high frequency rTMS to the left infero-parietal lobe, active/sham condition randomized (2:1), double-blind Transcranial Magnetic Stimulation (TMS): For rTMS, the coil is held flat on the scalp. 40 trains of 10 Hz rTMS will be delivered in trains lasting 4 seconds, with an intertrain interval of 26 seconds, for a total of 20 minutes (1600 pulses per day) at 100% motor threshold. Subjects will receive rTMS once a day, 5 days a week, for 4 weeks. During the first week of rTMS sessions only, in the event that the patient cannot tolerate these stimulation parameters, intensity relative to motor threshold may be titrated downward, in a masked fashion, to 80%, with all other dose parameters remaining the same.
Active High Frequency rTMS
Active high frequency rTMS to the left dorsolateral prefrontal cortex Transcranial Magnetic Stimulation (TMS): For rTMS, the coil is held flat on the scalp. 40 trains of 10 Hz rTMS will be delivered in trains lasting 4 seconds, with an intertrain interval of 26 seconds, for a total of 20 minutes (1600 pulses per day) at 100% motor threshold. Subjects will receive rTMS once a day, 5 days a week, for 4 weeks. During the first week of rTMS sessions only, in the event that the patient cannot tolerate these stimulation parameters, intensity relative to motor threshold may be titrated downward, in a masked fashion, to 80%, with all other dose parameters remaining the same.
Sham/Placebo
Sham (placebo) high frequency rTMS to the left dorsolateral prefrontal cortex or left infero-parietal lobe, active/sham condition randomized (2:1), double-blind Transcranial Magnetic Stimulation (TMS): For rTMS, the coil is held flat on the scalp. 40 trains of 10 Hz rTMS will be delivered in trains lasting 4 seconds, with an intertrain interval of 26 seconds, for a total of 20 minutes (1600 pulses per day) at 100% motor threshold. Subjects will receive rTMS once a day, 5 days a week, for 4 weeks. During the first week of rTMS sessions only, in the event that the patient cannot tolerate these stimulation parameters, intensity relative to motor threshold may be titrated downward, in a masked fashion, to 80%, with all other dose parameters remaining the same.
Open Cross Over High Frequency rTMS
Following the randomization phase with three arms, subjects who did not respond, have the possibility of receiving open active treatment to the target that they did not receive treatment to in the randomization phase. (i.e. randomized to IPL --\> open phase DLPFC and vice versa) repetitive transcranial magnetic stimulation: For rTMS, the coil is held flat on the scalp. 40 trains of 10 Hz rTMS will be delivered in trains lasting 4 seconds, with an intertrain interval of 26 seconds, for a total of 20 minutes (1600 pulses per day) at 100% motor threshold. Subjects will receive rTMS once a day, 5 days a week, for 4 weeks. During the first week of rTMS sessions only, in the event that the patient cannot tolerate these stimulation parameters, intensity relative to motor threshold may be titrated downward, in a masked fashion, to 80%, with all other dose parameters remaining the same.
Overall Study
STARTED
0
0
0
0
Overall Study
COMPLETED
0
0
0
0
Overall Study
NOT COMPLETED
0
0
0
0

Reasons for withdrawal

Withdrawal data not reported

Baseline Characteristics

Treatment of Negative Symptoms of Schizophrenia With Transcranial Magnetic Stimulation (TMS)

Baseline characteristics by cohort

Baseline data not reported

PRIMARY outcome

Timeframe: At baseline, every 2 weeks during rTMS sessions, and at monthly follow-up visits.

Population: P.I. has left the institution and NYSPI has no access to the data. Results will not be analyzed or presented.

Outcome measures

Outcome data not reported

SECONDARY outcome

Timeframe: At baseline, every 2 weeks during rTMS sessions, and at monthly follow-up visits.

Population: P.I. has left the institution and NYSPI has no access to the data. Results will not be analyzed or presented.

Outcome measures

Outcome data not reported

SECONDARY outcome

Timeframe: At baseline, every 2 weeks during rTMS sessions, and at monthly follow-up visits.

Population: P.I. has left the institution and NYSPI has no access to the data. Results will not be analyzed or presented.

Outcome measures

Outcome data not reported

SECONDARY outcome

Timeframe: At baseline, every 2 weeks during rTMS sessions, and at monthly follow-up visits.

Population: P.I. has left the institution and NYSPI has no access to the data. Results will not be analyzed or presented.

Outcome measures

Outcome data not reported

SECONDARY outcome

Timeframe: At baseline and the end of each study phase (random and open)

Population: P.I. has left the institution and NYSPI has no access to the data. Results will not be analyzed or presented.

Outcome measures

Outcome data not reported

SECONDARY outcome

Timeframe: At baseline, every 2 weeks during rTMS sessions, and at monthly follow-up visits.

Population: P.I. has left the institution and NYSPI has no access to the data. Results will not be analyzed or presented.

Outcome measures

Outcome data not reported

SECONDARY outcome

Timeframe: At baseline, the first and last rTMS sessions of each study phase (random and open), and at monthly follow-up visits.

Population: P.I. has left the institution and NYSPI has no access to the data. Results will not be analyzed or presented.

Outcome measures

Outcome data not reported

SECONDARY outcome

Timeframe: At baseline, every 2 weeks during rTMS sessions, and at monthly follow-up visits.

Population: P.I. has left the institution and NYSPI has no access to the data. Results will not be analyzed or presented.

Outcome measures

Outcome data not reported

Adverse Events

High Frequency rTMS

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

Active High Frequency rTMS

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

Sham/Placebo

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

Open Cross Over High Frequency rTMS

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

Serious adverse events

Adverse event data not reported

Other adverse events

Adverse event data not reported

Additional Information

Linda Sherman

New York State Psychiatric Institute

Phone: (646) 774-7158

Results disclosure agreements

  • Principal investigator is a sponsor employee
  • Publication restrictions are in place